Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model

BACKGROUND: The objective of this study was to investigate whether the therapeutic activity of sorafenib could be enhanced by combining with OGX-011, an antisense oligodeoxynucleotide (ODN) targeting clusterin, in renal cell carcinoma (RCC). METHODS: We investigated the effects of combined treatment...

Full description

Saved in:
Bibliographic Details
Main Authors: Kususda, Y, Miyake, H, Gleave, M E, Fujisawa, M
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2012
Subjects:
Translational Therapeutics
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3388571/
https://ncbi.nlm.nih.gov/pubmed/22588555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.209
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items